CompletedPhase 2

Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome

United Kingdom13 participantsStarted 2022-08-24

Plain-language summary

Aicardi-Goutières syndrome (AGS) is a disease of children, particularly affecting the brain and the skin. There is a close link between AGS and increased amounts of a chemical called interferon. Normally humans only produce interferon when they are infected with a virus. In AGS, there is no viral infection. Instead, the cells in the cells of affected patients are confused into thinking that their own genetic material is coming from a virus. As a result they produce interferon all the time, which acts as a poison that damages the cells. The Investigators wish to treat AGS patients with drugs called reverse transcriptase inhibitors (RTIs), used to fight the HIV-1 virus that causes AIDS. The investigators will monitor the effect of treatment on interferon levels, and look at other markers which might give us clues to how the drugs are working. The trial is funded by the Medical Research Council, and involves experts based in Edinburgh, Birmingham, Manchester and Great Ormond Street Hospital.

Who can participate

Age range3 Months – 15 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with mutations in any of TREX1, the three components of the RNase H2 complex (RNASEH2A, RNASEH2B, RNASEH2C: considered as one genotype) or SAMHD1. * Greater than age 3 months and less than 16 years of age at the time of recruitment * Resident in the United Kingdom (UK) * Informed Consent obtained from parent or personal legal representative * For inclusion in the study, a patient has either to have completed the vaccination programme two weeks prior to starting the trial, or remain unvaccinated until the end of the trial, or agree to defer vaccination until immediately after a study drug arm, so that there is a period of at least two weeks following vaccination and before the start of the following drug arm. Exclusion Criteria: * Patients with AGS due to mutations in ADAR1 and IFIH1 will not be considered, given that the induction of interferon relating to these genotypes does not involve a reverse transcription step. * Pre-existing disease, not due to AGS, which would preclude the use of zidovudine, lamivudine and abacavir * Patients with abnormally low neutrophil counts (\<0.75 x 109/l) and / or abnormally low haemoglobin levels (\<7.5 g/dl)(particularly relevant to zidovudine), significant renal (creatinine clearance \< 50 ml/min; particularly relevant to lamivudine) or significant hepatic impairment (particularly relevant to abacavir; avoid if Child Pugh \> 5) * Participation in another Clinical Trial of an Investigational Medicinal Produ…

What they're measuring

Determine if the use of the reverse transcriptase inhibitors abacavir (ABC), lamivudine (3TC) and zidovudine (AZT) reduces Interferon (IFN) signalling in patients with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C or SAMHD1

Timeframe: At 6 weeks

Trial details

NCT IDNCT04731103

SponsorUniversity of Edinburgh

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03-11